Involvement of Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 in Corneal Fibroblasts during Corneal Wound Healing

Kanako Izumi,1,2 Daijiro Kurosaka,1 Takeshi Iwata,2 Yoshibisa Oguchi,1 Yasubiko Tanaka,2 Yukibiko Mashima,1 and Kazuo Tsubota1

PURPOSE. The involvement of downstream messengers of transforming growth factor (TGF)-β in the differentiation of corneal fibroblasts into myofibroblasts was investigated. The effects of insulin-like growth factor (IGF)-I and insulin-like growth factor binding protein (IGFBP)-3 upregulated by TGF-β were examined in human corneal fibroblasts, and the possible involvement of IGF axis components in corneal wound healing was assessed in a mouse model.

METHODS. Human corneal fibroblasts were incubated with TGF-β2 or IGF-I, to investigate IGF-I, IGF-II, IGFBP-3, type I collagen, α-smooth muscle actin (α-SMA) mRNA, as well as IGFBP-3 protein expression, during myofibroblast differentiation. DNA synthesis was evaluated with a 5-bromo-2'-deoxyuridine (BrdU) incorporation assay. IGFBP-3 mRNA expression, protein expression, and immunolocalization were investigated in mouse corneas after photorefractive keratectomy (PRK).

RESULTS. TGF-β2 treatment induced expression of IGF-I and IGFBP-3 mRNA and of IGFBP-3 protein in human corneal fibroblasts. TGF-β2 and IGF-I both stimulated expression of type I collagen. TGF-β2 but not IGF-I potentiated activated α-SMA mRNA expression. IGF-I potently stimulated basal DNA synthesis, whereas IGFBP-3 inhibited it. IGF-I potentiated proliferation of TGF-β2-activated myofibroblasts without reversing the activated fibrogenic phenotype, whereas IGFBP-3 inhibited IGF-I-induced proliferation of corneal fibroblasts. IGFBP-3 mRNA and protein increased in mouse corneas soon after PRK, when in vivo immunostaining of the corneal stroma showed expression of IGFBP-3 in the deep layer of the corneal stroma.

CONCLUSIONS. These results suggest that during corneal wound healing, TGF-β stimulates IGF-I axis components, whereas IGFBP-3 may modulate IGF-I-induced myofibroblast proliferation to suppress corneal mesenchymal overgrowth.

During corneal wound healing leading to scar formation, keratocytes are activated, turn into fibroblasts, and eventually transformed into α-smooth muscle actin (α-SMA)-expressing myofibroblasts.1–5 Myofibroblasts are central to wound healing, as they generate the contractile forces necessary for wound closure.4,6,7 However, regulation of myofibroblast differentiation and proliferation is crucial, because an excessive number of myofibroblasts results in excessive scar formation.8 Soluble mediators of wound repair, such as growth factors, are important in regulating myofibroblast differentiation and proliferation.

The differentiation of keratocyte into myofibroblasts has been shown to be induced by TGF-β3–5,9. TGF-β isoforms regulate multiple biological processes including cell proliferation, extracellular matrix synthesis, angiogenesis, immune response, apoptosis, and differentiation.7,10–12 They have been implicated in the pathogenesis of fibrosis, autoimmune diseases, cancer, and other disorders.7,10–12 TGF-β is a pluripotent cytokine capable of inhibiting or stimulating cell growth, depending on the nature of the target cell.13 TGF-β is a potent inhibitor of growth in a variety of epithelial cell types, whereas in stromal cells it stimulates cell growth.12,13

Growth-promoting and metabolic regulatory activities of insulin-like growth factor (IGF)-I and -II are modulated by a family of six high-affinity insulin-like growth factor binding proteins (IGFBPs) and mediated by two IGF receptors (IGF-IR and -IIR), particularly IGF-IR.14–16 Modulation of IGF actions by IGFBP may be positive or negative, depending on tissue type and physiologic or pathologic states.15,17–20

IGFBP-3 is one of the six IGFBPs that regulate binding of IGF-I with the cognate IGF-I receptor tyrosine kinase.20–25 By modulating the binding of IGF-I to its receptor, an individual IGFBP can either inhibit or augment IGF-I-stimulated growth.21–24 IGFBP-3 is a 40- to 45-kDa glycoprotein produced locally in many tissues, where it serves important paracrine and autocrine functions in modulating cellular growth and apoptosis.22,25,26 IGFBP-3 activity at the cellular level is regulated, not only by its rate of synthesis, but also by post-translational modification and proteolysis.29 Several IGFBP-3 proteases have been identified, including plasmin, matrix metalloproteinases, kallikreins, prostate-specific antigen, and cathepsin D. This proteolysis results in IGFBP-3 fragments with a low affinity for IGFs.30,51 IGFBP-3, like IGFBP-1 and IGFBP-5, is capable of regulating cell growth independent of its effects on IGF-stimulated growth.52 For example, IGFBP-3 inhibits replication and promotes apoptosis in various cell lines in an IGF-independent manner.52 Not only IGF-1 but TGF-β1 and TGF-β2 enhance IGFBP-3 mRNA and protein expression in both epithelial and stromal cell types.53–55 The IGF system plays an important role in wound healing,14,15 and both IGF-I and IGFBP-3 are present in wound fluid in significant concentrations.14,15,19

To our knowledge, the IGFBP-3 system has not been investigated in corneal wound healing. To test our hypothesis that IGF axis components regulate corneal scar formation, we investigated whether TGF-β2 induces IGF-I and IGFBP-3 expression and whether IGFBP-3 modulates IGF-I-induced myofibroblast proliferation in cultured corneal fibroblasts. We then evaluated expression and localization of IGFBP-3 in mouse cornea after photorefractive keratectomy (PRK).
Materials and Methods

Cell Culture

Human corneal fibroblasts were isolated from corneal limbal rims donated by the Northwest Lions Eye Bank (Seattle, WA). Procedures used in this human-cell in vitro research conformed to the tenets of the Declaration of Helsinki. Corneal tissue was cut into pieces and incubated in a humidified atmosphere of 5% CO₂ and 95% air at 37°C in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen-Gibco, Grand Island, NY) containing 10% fetal bovine serum (FBS; Invitrogen-Gibco). Cells in the third passage were used for experiments. The purity of cell cultures was assessed by determining the reactivity with antibodies to vimentin by immunofluorescence analysis. All fibroblasts were immunonegative for vimentin but not for cytokeratin, suggesting the absence of contamination by epithelial cells.

For reverse-transcription polymerase chain reaction (RT-PCR) experiments, human corneal fibroblasts were cultured at a density of \(6.0 \times 10^3/\text{mL}\) in serum-free medium. After 24 hours, this medium was replaced with serum-free medium containing TGF-β2 (0.01–100 ng/mL; R&D Systems, Minneapolis, MN), IGF-I (50 ng/mL; R&D Systems), and anti-IGF-I neutralizing antibody (20 μg/mL; R&D Systems). Incubation was continued for 12, 24, 48, or 72 hours before RNA was extracted for analysis.

For Western blot analysis, human corneal fibroblasts were cultured at a density of \(6.0 \times 10^4/\text{mL}\) in serum-free medium. After 24 hours, this medium was replaced with serum-free medium containing 1 ng/mL TGF-β2 for incubations continuing a further 12, 24, 48, or 72 hours before collection of medium for analysis. The conditioned medium was collected, centrifuged to remove cell debris, and stored at \(-80°C\) until use.

Photorefractive Keratectomy

Animal procedures were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Six- to 8-week-old mice (C57BL/6) were used. To induce corneal wounds, first we anesthetized mice by an intraperitoneal injection of 10% pentobarbital (0.15 mg/10 g body weight). A drop of proparacaine HCl (0.05%) was applied to the eye, and the cornea was centered around the laser microtome. Two-millimeter corneal wounds were produced in the right eye of each animal by transepithelial excimer laser ablation (2-mm optical zone; 42- to 44-μm ablation depth; PTK mode; model EC5000; Nidek, Yokohama, Japan). After excimer laser treatment, tobramycin ointment (0.3%) was applied to the corneal wounds, first we anesthetized mice by an intraperitoneal injection of 10% pentobarbital (0.15 mg/10 g body weight). A drop of proparacaine HCl (0.05%) was applied to the eye, and the cornea was centered around the laser microtome. Two-millimeter corneal wounds were produced in the right eye of each animal by transepithelial excimer laser ablation (2-mm optical zone; 42- to 44-μm ablation depth; PTK mode; model EC5000; Nidek, Yokohama, Japan). After excimer laser treatment, tobramycin ointment (0.3%) was applied to the corneal surface to prevent infection. No postoperative topical steroid was administered. At 12 hours and 1, 3, 7, and 14 days after excimer laser ablation, mice were euthanized for excision of corneas under an operating microscope, these were stored at \(-80°C\) until analysis. At 12 hours and 24, 48, or 72 hours after transfer, the membrane was rinsed three times with TBS-0.1% Tween, and then incubated with horseradish peroxidase-labeled goat antirabbit IgG (Jackson ImmunoResearch Laboratories) or a polyclonal rabbit antibody against mouse IGFBP-3 (GroPep, Adelaide, Australia). Specific binding was detected by an Alexa 488-conjugated anti-rabbit secondary antibody against mouse IGFBP-3 (GroPep) for 2 hours at room temperature. The membrane was rinsed with TBS containing 5% skim milk for 1 hour at room temperature. The membrane was rinsed three times with TBS-0.1% Tween, and then incubated with an anti-human IGFBP-3 monoclonal antibody (R&D Systems) or a polyclonal rabbit antibody against mouse IGFBP-3 (GroPep) for 2 hours at room temperature. The membrane was rinsed with TBS-0.1% Tween and then incubated with horseradish peroxidase-labeled goat anti-rabbit IgG (Jackson ImmunoResearch Laborato-

IGFBP-3 Immunohistochemistry in Mouse Corneal Sections

Eyes harvested at each time point were incubated in 4% paraformaldehyde and phosphate-buffered saline (PBS) overnight at 4°C. Paraffin-embedded sections were cut at a 4-μm thickness and affixed to glass slides (Superfrost; Matsunami, Osaka, Japan). Formalin-fixed paraffin-embedded sections of tissue were heated, dewaxed, and rehydrated before blocking of endogenous peroxidase (0.1%, vol/vol hydrogen peroxide). Sections were incubated with polyclonal rabbit antibody against mouse IGFBP-3 (GroPep, Adelaide, Australia). Specific binding was detected by an Alexa 488-conjugated anti-rabbit secondary antibody (Molecular Probes, Eugene, OR). The sections were counterstained with propidium iodide, and mounted in anti-fading solution (Vector Laboratories, Burlingame, CA). In addition to the fluorescent conjugate, primary antibody was detected with an immunoperoxidase protocol (Envision kit; Dako, Ely, UK). Fluorescent images were photographed with a laser scanning confocal microscope (LSM510; Carl Zeiss Meditec, Jena, Germany).

Western Blot Analysis

For Western blot analysis, 10 ml serum-free conditioned medium collected from each flask was concentrated by centrifugation in a spin column (Centricron 50; Millipore, Bedford, MA) to achieve a 200-fold concentration. Protein from the concentrated conditioned medium of corneal fibroblasts or protein extracted from mouse cornea after PRK was analyzed for IGFBP-3 on 15% SDS-polyacrylamide gels and then electrophoretically transferred to polyvinylidene difluoride (PVDF) membrane. Overall protein concentrations were determined by the Lowry assay. Transfer was performed at a constant voltage of 60 V for 1 hour. After transfer, the membrane was incubated in Tris-buffered saline (TBS) containing 5% skim milk for 1 hour at room temperature. The membrane was rinsed three times with TBS-0.1% Tween, and then incubated with an anti-human IGFBP-3 monoclonal antibody (R&D Systems) or a polyclonal rabbit antibody against mouse IGFBP-3 (GroPep) for 2 hours at room temperature. The membrane was rinsed with TBS-0.1% Tween and then incubated with horseradish peroxidase-labeled goat anti-rabbit IgG (Jackson ImmunoResearch Laborato-

**Downloaded From:** http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933234/ on 10/16/2017
FIGURE 1. TGF-β2 stimulation of IGFBP-3 production by corneal fibroblasts. (A) IGFBP-3 mRNA expression in the presence of various concentrations of TGF-β2. Corneal fibroblasts were incubated for 24 hours in serum-free medium in the absence or presence of TGF-β2 at concentrations ranging from 0.01 to 100 ng/mL. The relative amount of IGFBP-3 mRNA compared with that in the untreated control was determined by real-time quantitative PCR.*Significantly different (P < 0.05) from the serum-free control. (B) Time course of IGFBP-3 mRNA expression in corneal fibroblasts after treatment with 1 ng/mL TGF-β2. The relative amount of IGFBP-3 mRNA compared with the untreated control was determined by real-time quantitative PCR. **Significantly different (P < 0.05) from 0-hour control. (C) Western blot of conditioned medium, performed to determine the time course of IGFBP-3 secretion from corneal fibroblasts. Media from untreated cells or cells treated for 12, 24, 48, or 72 hours with 1 ng/mL TGF-β2 were concentrated and subjected to immunoblot analysis with an antibody against IGFBP-3. Data are representative of results in three independent experiments.

Assays of DNA Synthesis

The effect of TGF-β2, IGF-I, and IGFBP-3 on corneal fibroblast proliferation was assessed by BrdU incorporation using a BrdU enzyme-linked immunosorbent assay (ELISA; Cell Proliferation ELISA, BrdU colorimetric; Roche Diagnostics) according to the instructions of the manufacturer. Corneal fibroblasts were cultured in 96-well plates (2.8 × 10³ per well) for 24 hours in DMEM containing 0.1% bovine serum albumin (BSA), after which the culture medium was further supplemented with growth factors. Control cultures were incubated in the absence of growth factor. To study the effect of exogenous TGF-β2, IGF-I, and IGFBP-3 on DNA synthesis, we incubated corneal fibroblasts for 24 hours in the presence of TGF-β2 (0.01-10 ng/mL), IGF-I (50 ng/mL), IGFBP-3 (50-1000 ng/mL), and immunoneutralizing antibody against IGFBP-3 (10 µg/mL; R&D Systems). Cells were pulse labeled with BrdU for 24 hours with 100 µM BrdU. All assays were performed in triplicate or quadruplicate and were replicated in at least two separate experiments.

Statistical Analysis

Data are presented as the mean ± SD and were analyzed by one-way analysis of variance (ANOVA). Post hoc comparisons between groups used the Fisher protected least significant difference test. P < 0.05 was accepted as indicating statistical significance. All experiments in this study were repeated at least three times, in the same conditions.

RESULTS

Induction of IGFBP-3 Expression by TGF-β2 in Human Corneal Fibroblasts

We began the present study by asking whether TGF-β2-treated human corneal fibroblasts express IGFBP-3 at the mRNA and protein levels, using real-time quantitative PCR and Western blot analysis. Figure 1A shows that treatment with TGF-β2 significantly stimulated the expression of endogenous IGFBP-3 in a TGF-β2 dose-dependent manner (Fig. 1B). As for time, 1 ng/mL TGF-β2 increased IGFBP-3 protein production within 24 hours of addition (Fig. 1C), after 72 hours, the degree of stimulation was much greater.

Effect of IGFBP-3 on DNA Synthesis by Corneal Fibroblasts

We next asked how IGFBP-3 affects corneal fibroblast DNA synthesis. Addition of IGFBP-3 to corneal fibroblasts significantly inhibited basal DNA synthesis in a dose-dependent manner.

FIGURE 2. Effect of IGFBP-3 on DNA synthesis in human corneal fibroblasts. Cells were cultured for 24 hours in DMEM containing 0.1% BSA in the absence or presence of IGFBP-3 at concentrations ranging from 50 to 1000 ng/mL, or in the presence of 10 µg/mL IGFBP-3 neutralization antibody (BP-3 Ab). Cells were pulse-labeled with BrdU for 24 hours. Data represent the mean ± SD of results in three experiments, in which determinations were performed in triplicate. *Significantly different (P < 0.05) from the serum-free control.
ner (Fig. 2), whereas basal DNA synthesis in corneal fibroblasts was increased in the presence of the IGFBP-3-neutralizing antibody. The result implied that endogenous IGFBP-3 directly inhibits corneal fibroblast proliferation.

Induction of IGF mRNA Expression by TGF-β2 in Human Corneal Fibroblasts

Next, we investigated the effect of TGF-β2 on expression of other components of the IGF axis. RT-PCR was used to determine whether mRNA expression of IGFs is altered by TGF-β2. Treatment with TGF-β2 stimulated expression of endogenous IGF-I mRNA but not that of IGF-II mRNA (Fig. 3A). As shown in Figure 3B, TGF-β2 induced IGF-I expression in a dose-dependent manner.

Effect of TGF-β2 and IGF-I on Type I Collagen and α-SMA mRNA Expression

We next assessed the effect of IGF-I and TGF-β2 on type I collagen and α-smooth muscle actin expression. As shown in Figure 4, in cells treated for 48 hours, IGF-I and TGF-β2 induced a similar increase in type I collagen mRNA. Furthermore, corneal fibroblasts treated with TGF-β2 and anti IGF-I neutralizing antibody also induced significant upregulation of COLIA1 mRNA compared with the untreated control. Treatment with TGF-β2 and anti-IGF-I neutralizing antibody significantly suppressed this expression compared with TGF-β2 treatment. In contrast, although TGF-β2 treatment resulted in a fivefold increase in α-SMA mRNA expression, no α-SMA mRNA increase was detected in response to IGF-I.

Effect of TGF-β2 and IGF-I on DNA Synthesis by Corneal Fibroblasts

To determine whether addition of TGF-β2 or IGF-I to corneal fibroblasts affects DNA synthesis, we used a BrdU incorporation assay. As shown in Figure 5, incubation with IGF-I for 24 hours significantly stimulated DNA synthesis in cultured corneal fibroblasts compared with the untreated control. Whereas a low concentration of TGF-β2 enhanced corneal fibroblast DNA synthesis, a high concentration inhibited it.
Effect of IGF-I on Proliferation and Characteristics of Corneal Myofibroblasts Induced by TGF-β2

We next asked whether TGF-β2 and IGF-I act sequentially in regulating the activated myofibroblast phenotype or cell proliferation. Cells were pretreated with TGF-β2, followed by substitution of medium containing IGF-I but not TGF-β2. Cells pretreated with TGF-β2 for 7 days showed a significant increase in DNA synthesis when subsequently exposed to IGF-I instead (Fig. 6A). To determine whether IGF-I affects the activated phenotype induced by TGF-β2, cells pretreated with TGF-β2 for 7 days were exposed to serum-free medium, with or without IGF-I, for 3 days and then immunostained for α-smooth muscle actin. A large percentage of corneal fibroblasts that expressed α-smooth muscle actin after 7 days of TGF-β2 treatment maintained the expression of α-SMA after exposure for 3 days to serum-free medium or IGF-I. The activated phenotype therefore was not reversed spontaneously or by IGF-I over this time frame (Fig. 6B).

Modulation of Basal and IGF-I-Stimulated DNA Synthesis by IGFBP-3

Interaction between IGFBP-3 and IGF-I or TGF-β2 then was considered in terms of DNA synthesis by corneal fibroblasts. When added to medium together with IGF-I, IGFBP-3 significantly inhibited IGF-I-stimulated DNA synthesis. However, IGFBP-3 did not affect the inhibitory effect of 1 ng/mL TGF-β2 on basal DNA synthesis (Fig. 7) or TGF-β2-stimulated expression of α-SMA and type I collagen (data not shown).

Effect of PRK on IGFBP-3 mRNA and Protein Levels in Mouse Cornea

To investigate the involvement of IGFBP-3 in corneal wound healing in vivo, we studied IGFBP-3 expression in mouse corneal fibroblasts.
IGFBP-3 Localization in Mouse Cornea after PRK

Localization of IGFBP-3 during mouse corneal wound healing after PRK was examined by immunostaining. As shown in Figure 9, IGFBP-3 was immunolocalized in paraflin-embedded sections of mouse corneas harvested at the same time points after surgery at which protein and RNA were measured. IGFBP-3 was detected in only slight amounts in the stromal matrix of normal corneas before PRK (day 0). On day 1 after surgical injury, intense staining was present in the deep layer of the corneal stroma. By day 7, staining in the deep stromal layer was reduced, in agreement with the results of Western blot analysis.

DISCUSSION

IGFBP-3, the major serum transport protein for IGFs, also is active in the cellular environment, where it acts as a potent antiproliferative agent.\textsuperscript{22,23,28} We found that in human corneal fibroblasts, TGF-β induced expression of IGFBP-3 mRNA and protein, whereas IGFBP-3 inhibited DNA synthesis in corneal fibroblasts. In addition to its effect on IGFBP-3, TGF-β induced IGF-1 mRNA expression. IGF-I promoted proliferation of myofibroblasts without reversing the activated phenotype. We conclude that during corneal wound healing, IGF axis components are likely to regulate corneal mesenchymal overgrowth and suppress corneal stromal wound contraction.

TGF-β is a well-established mediator of wound healing and fibrosis in several organs.\textsuperscript{36} In the cornea, it potently activates keratocytes to a myofibroblast phenotype expressing α-SMA and also induces expression of type I collagen.\textsuperscript{3–5,9} Previous reports of potent upregulation of IGFBP-3 by TGF-β in subconfluent fibroblasts\textsuperscript{34,35} were confirmed in our corneal cells in subconfluent, serum-free culture. In accord with evidence that IGFBP-3 plays a role in antiproliferation,\textsuperscript{25,26} IGFBP-3 appeared to suppress proliferation of myofibroblasts induced by TGF-β. Potentiation and inhibition of IGF action by IGFBP-3 have been demonstrated in many cell culture systems.\textsuperscript{17–18,22} It is thought that cotreatment of cells with IGFBP-3 and IGF-I causes...
IGFBP-3 to inhibit IGF-I-mediated effects via high-affinity sequestration of the ligand, presumably leading to prevention of IGF-I-induced autophosphorylation and signaling. In cornea, epithelial cells and fibroblasts express IGF-I, IGF-II, and IGFR. IGFBP-3 is suggested to play a critical role in the maintenance of the keratocyte phenotype and protective against apoptosis. IGFBP-3 has also been shown to be chemotactic for human corneal fibroblasts, and to enhance epidermal growth factor stimulated collagen gel contraction. The effects of TGF-β on IGFBP-3 mRNA observed in our present experiments have important implications for regulation of corneal mesenchymal overgrowth during corneal wound healing. Our new observations that TGF-β induces expression of IGFBP-3 in corneal fibroblasts and that IGF-I stimulates growth of corneal fibroblasts activated to a myofibroblast phenotype by TGF-β suggest that such regulation may take place during corneal stromal wound healing. The myofibroblast phenotype was not reversed by IGF-I. Furthermore, our study supports a role for IGFBP-3, together with TGF-β2, as an upregulator of extracellular matrix (ECM) synthesis during corneal stromal wound healing. IGF-I, then, is critical not only to maintenance of the keratocyte phenotype in intact cornea, but to regulation of myofibroblast behavior in injured cornea. These aspects of IGF-I activity in corneal wound healing currently are being studied in corneal cell culture.

Our findings that TGF-β induced upregulation of IGFBP-3 mRNA by 12 hours after TGF-β treatment and that immunoneutralization of endogenous IGFBP-3 increased basal DNA synthesis in corneal fibroblasts suggest possible IGF-independent effects of IGFBP-3. In several carcinoma cell lines and in some normal cells, IGFBP-3 regulates cell growth independent of IGF-I. Two mechanisms for this effect have been identified: the first involves the interaction of IGFBP-3 with TGF-β receptors and TGF-β-dependent signaling mechanisms, the second involves the interaction of IGFBP-3 with nuclear retinoid receptor-α (RXR-α). Furthermore, recent studies have shown that endogenous IGFBP-3 directly inhibits proliferation of human intestinal smooth muscle cells by activation of TGF-βRI and Smad2. Although this IGFBP-3-dependent inhibition of growth is mediated via TGF-β receptors, these effects are independent of endogenous TGF-β because immunoneutralization of endogenous TGF-β does not diminish IGFBP-3-dependent Smad2 activation or IGFBP-3-dependent inhibition of [3H] thymidine incorporation. Therefore, one may postulate that IGFBP-3 also inhibits corneal fibroblast growth directly, helping to prevent excessive proliferation of fibroblasts before their differentiation to the activated phenotype in the wound cornea.

The ability of IGFBP-3 to bind other molecules has been demonstrated previously. Recent studies have shown that plasminogen binds IGFBP-3 and the binary IGF-I/IGFBP-3 complex with high affinity by interacting directly with the IGFBP-3 heparin-binding domain. In vitro studies have shown that hypertrophic scar fibroblasts produce elevated levels of IGFBP-3 and type I collagen and that TNFα treatment reduces IGFBP-3 and collagen expression in a dose-dependent fashion. A recent report indicated that physiologic effects of IGFBP-3-collagen interaction may include modulation of cell adhesion and migration because they characterized type I collagen as one of the IGFBP-3 binding proteins. In our present in vivo experiments, strong IGFBP-3 immunoreactivity was found in the extracellular matrix of mouse corneal stroma at an early time point during wound healing after PRK. This IGFBP-3 may bind to the collagen matrix and contribute to regulation of corneal stromal wound healing.

After refractive surgery, a corneal subepithelial haze develops in some patients as a wound healing response. This reaction has been reported to be associated with increased myofibroblast transformation. When it follows PRK, the corneal haze develops in the subepithelial lesion, not in the deep stromal layer. We found immunostaining for IGFBP-3 at an early time point after PRK to be much stronger in the deep stromal than subepithelially. IGFBP-3, then, may act to suppress formation of haze by inhibiting the proliferation of corneal myofibroblasts. Pathologic fibrosis and myofibroblast formation induced by TGF-β within the eye represents a significant pathophysiologic problem and may lead, not only to a subepithelial corneal haze, but to various other adverse effects, such as posterior capsular opacification, anterior subcapsular cataract, and trabeculectomy bleb failure. As yet, no report has characterized the activity of IGFBP-3 in these conditions. Our study may expand the possibilities for preventing these adverse effects, because IGFBP-3 has hidden potential to become a key factor in various fibroses and wound contraction.

We present evidence of the induction of IGFBP-3 by TGF-β treatment of corneal fibroblasts. We found that the combined actions of TGF-β and IGF-I would stimulate collagen synthesis in healing, whereas proliferation would be limited by IGFBP-3 induced by TGF-β. Persistent expression of IGF-I in cells exposed to TGF-β would permit proliferation of myofibroblasts, resulting in fibrosis. It is noteworthy that the effect of TGF-β2 to induce both IGF-I and IGFBP-3 indicates that, if such an effect occurs in vivo, the spatial and temporal distribution of IGF-I and IGFBP-3 may have major effects on the degree to which fibrogenic populations of myofibroblasts are expanded. The current report demonstrates that IGFBP-3 induced by TGF-β may be critical in the suppression of mesenchymal overgrowth after corneal injury.

References


